MedTrace Logo

Enteroadsorbent Polymethylsiloxane vs Probiotic Lactobacillus Reuteri in the Treatment of Rotaviral Gastroenteritis

NCT04116307 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2019-10-04

No results posted yet for this study

Summary

This study evaluates a new drug, new enteroadsorbent polymethylsiloxane (Enterosgel) in the treatment of rotavirus gastroenteritis in children. Half of the participants received a new drug, polymethylsiloxane and half of the participants received standard treatment - probiotic L. reuteri (BioGaia).

Conditions

  • Rotavirus Gastroenteritis

Interventions

DIETARY_SUPPLEMENT

Polymethylsiloxane

DIETARY_SUPPLEMENT

Lactobacillus reuteri

Sponsors & Collaborators

  • University Hospital for Infectious Diseases, Croatia

    lead OTHER

Principal Investigators

  • Goran Tešović, MD, PhD · University Clinic for Infectious Diseases, Zagreb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04116307 on ClinicalTrials.gov